FibroScan分别与GPR、APRI、NFS、FIB-4联合应用对慢性乙型肝炎合并非酒精性脂肪性肝病进展期肝纤维化的诊断价值比较

龚航; 李良平

doi:10.3969/j.issn.1001-5256.2020.03.014

FibroScan分别与GPR、APRI、NFS、FIB-4联合应用对慢性乙型肝炎合并非酒精性脂肪性肝病进展期肝纤维化的诊断价值比较

DOI: 10.3969/j.issn.1001-5256.2020.03.014

龚航,
李良平

1. 自贡市第一人民医院消化内科
2. 四川省医学科学院·四川省人民医院消化内科

基金项目:

四川省卫计委重点课题(16ZD024)；

详细信息

中图分类号: R512.62;R575.5
计量
- 文章访问数: 1311
- HTML全文浏览量: 66
- PDF下载量: 251
- 被引次数: 0
出版历程
- 出版日期: 2020-03-20

Value of Fibroscan combined with GPR,APRI,NFS or FIB-4 for progressive liver fibrosis in patients with chronic hepatitis B and nonalcoholic fatty liver disease

Department of Gastroenterology, The First People’s Hospital of Zigong

Research funding:

摘要

摘要: 目的评价FibroScan、GPR、APRI、NFS、FIB-4单独应用及FibroScan分别与GPR、APRI、NFS、FIB-4联合应用对慢性乙型肝炎（CHB）合并非酒精性脂肪性肝病（NAFLD）患者进展期肝纤维化的诊断价值。方法选取2014年11月-2018年8月在四川省人民医院行肝穿刺病理检查并确诊为CHB合并NAFLD的患者92例。根据肝穿刺病理SAF分级诊断标准,分为轻中度肝纤维化（F1+F2）组（n=69）和进展期肝纤维化（F3）组（n=23）。同时应用FibroScan测得肝脏硬度值,根据临床指标分别计算GPR、APRI、NFS、FIB-4。计量资料两组间比较采用Mann-Whitney U检验;相关性分析采用Spearman秩相关;多因素二元logistic回归构建联合预测因子（向前逐步回归法）,绘制受试者工作特征曲线（ROC曲线）,计算ROC曲线下面积（AUC）,并采用Delong方法进行比较,评价各种无创诊断方法单独及联合应用对CHB合并NAFLD进展期肝纤维化的诊断价值。结果轻中度肝纤维化组的FibroScan、GPR、APRI、NFS及FIB-4水平明显低于...
- 乙型肝炎,慢性 /
- 非酒精性脂肪性肝病 /
- 肝硬化 /
- 诊断
Abstract: Objective To investigate the diagnostic value of FibroScan,gamma-glutamyl transpeptidase-to-platelet ratio( GPR),aspartate aminotransferase-to-platelet ratio index( APRI),nonalcoholic fatty liver disease( NAFLD) fibrosis score( NFS),and fibrosis-4( FIB-4) used alone or FibroScan combined with GPR,APRI,NFS,or FIB-4 for progressive liver fibrosis in patients with chronic hepatitis B( CHB) and NAFLD. Methods A total of 92 patients who underwent liver biopsy in Sichuan Provincial People's Hospital from November 2014 to August 2018 and were diagnosed with CHB and NAFLD were enrolled. Based on the SAF scoring system for liver biopsy,these patients were divided into mild-to-moderate liver fibrosis( F1 + F2) group with 69 patients and progressive liver fibrosis( F3) group with 23 patients. FibroScan was used to obtain liver stiffness measurement( LSM),and GPR,APRI,NFS,and FIB-4 were calculated based on clinical indices. The Mann-Whitney U test was used for comparison of continuous data between two groups. Spearman rank correlation was used for correlation analysis. A multivariate binary logistic regression analysis( forward stepwise regression) was used to construct combined predictive factors. The receiver operating characteristic( ROC) curve was plotted,and the area under the ROC curve( AUC) was calculated,and Delong method was used to compare the AUC to evaluate the early-warning value of each noninvasive diagnostic method used alone or in combination in the diagnosis of CHB and progressive liver fibrosis. Results The mild-to-moderate liver fibrosis group had significantly lower values of FibroScan,GPR,APRI,NFS,and FIB-4 than the progressive liver fibrosis group( Z =-4. 910,-3. 425,-3. 837,-3. 873,and-3. 990,all P < 0. 05). The correlation analysis showed that FibroScan,GPR,APRI,NFS,and FIB-4 were positively correlated with the pathological staging of liver fibrosis( r = 0. 518,0. 361,0. 405,0. 407,and 0. 418,P < 0. 05). FibroScan,GPR,APRI,NFS,and FIB-4 used alone had a certain clinical value in the diagnosis of progressive liver fibrosis( AUC = 0. 844,0. 740,0. 770,0. 771,and 0. 779,all P < 0. 001),while FibroScan was not superior to GPR,APRI,NFS,and FIB-4( P > 0. 05). FibroScan combined with GPR,APRI,NFS,or FIB-4 had a significantly higher AUC than GPR,APRI,NFS,or FIB-4 used alone in the diagnosis of progressive liver fibrosis( Z = 1. 977,2. 076,2. 361,and 2. 206,all P < 0. 05). FibroScan combined with these four indices had an AUC of 0. 896( 95% confidence interval: 0. 813-0. 950). Conclusion FibroScan,GPR,APRI,NFS,and FIB-4 have a certain clinical value in the diagnosis of progressive liver fibrosis,and FibroScan combined with GPR,APRI,NFS,or FIB-4 has higher efficiency than GPR,APRI,NFS,or FIB-4 used alone in the diagnosis of progressive liver fibrosis,among which FibroScan combined with NFS or FIB-4 may have the best clinical value.
- hepatitis B,chronic /
- non-alcoholic fatty liver disease /
- liver cirrhosis /
- diagnosis

HTML全文

参考文献(16)

[1] WONG VW,WONG GL,CHU WC,et al. Hepatitis B virus infection and fatty liver in the general population[J]. J Hepatol,2012,56(3):533-540.

[2] ZHU L,JIANG J,ZHAI X,et al. Hepatitis B virus infection and risk of non-alcoholic fatty liver disease:A population-based cohort study[J]. Liver Int,2019,39(1):70-80.

[3] YANG RX,FAN JG. Characteristics,diagnosis and management of concomitant fatty liver in hepatitis B patients[J]. Chin J Clin Infect Dis,2018,11(3):174-178.(in Chinese)杨蕊旭，范建高．乙型肝炎合并脂肪肝的特征和诊治对策[J]．中华临床感染病杂志，2018,11(3):174-178.

[4] WILDER J,PATEL K. The clinical utility of FibroScanas a noninvasive diagnostic test for liver disease[J]. Med Devices(Auckl),2014,7:107-114.

[5] LU XJ,LI XH,YUAN ZX,et al. Assessment of liver fibrosis with the gamma-glutamyl transpeptidase to platelet ratio:A multicentre validation in patients with HBV infection[J]. Gut,2018,67(10):1903-1904.

[6] ZHANG DK,CHEN M,LIU Y,et al. The diagnostic value of ARFI imaging and APRI for quantitative evaluating the degree of liver fibrosis in NAFLD patients[J]. J Chin Clin Med Imaging,2013,24(3):178-181,187.(in Chinese)张大鹍，陈敏，刘阳，等．ARFI与APRI指数对非酒精性脂肪性肝病肝纤维化的诊断价值[J]．中国临床医学影像杂志，2013,24(3):178-181,187.

[7] SUN W,CUI H,LI N,et al. Comparison of FIB-4 index,NAFLD fibrosis score and BARD score for prediction of advanced fibrosis in adult patients with non-alcoholic fatty liver disease:A meta-analysis study[J]. Hepatol Res,2016,46(9):862-870.

[8] CHALASANI N,YOUNOSSI Z,LAVINE JE,et al. The diagnosis and management of nonalcoholic fatty liver disease:Practice guidance from the American Association for the Study of Liver Diseases[J]. Hepatology,2018,67(1):328-357.

[9] National Workshop on Fatty Liver and Alcoholic Liver Disease,Chinese Society of Hepatology,Chinese Medical Association;Fatty Liver Expert Committee,Chinese Medical Doctor Association. Guidelines of prevention and treatment for nonalcoholic fatty liver disease:A 2018 update[J]. J Clin Hepatol,2018,34(5):947-957.(in Chinese)中华医学会肝病学分会脂肪肝和酒精性肝病学组，中国医师协会脂肪性肝病专家委员会．非酒精性脂肪性肝病防治指南(2018年更新版)[J]．临床肝胆病杂志，2018,34(5):947-957.

[10] Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association. The guideline of prevention and treatment for chronic hepatitis B:A 2015 update[J]. J Clin Hepatol,2015,31(12):1941-1960.(in Chinese)中华医学会肝病学分会，中华医学会感染病学分会．慢性乙型肝炎防治指南(2015年更新版)[J]．临床肝胆病杂志，2015,31(12):1941-1960.

[11] European Association for the Study of the Liver(EASL); European Association for the Study of Diabetes(EASD); European Association for the Study of Obesity(EASO). EASL-EASDEASO clinical practice guidelines for the management of nonalcoholic fatty liver disease[J]. J Hepatol,2016,64(6):1388-1402.

[12] KUMAR R,BOON-BEE GOH G. Chronic hepatitis B and fatty liver:Issues in clinical management[J]. Clin Res Hepatol Gastroenterol,2016,40(6):755-759.

[13] ZENG CM,LU SY,GUO TL,et al. The relationship between hepatic steatosis and chronic hepatitis B and the effects on liver fibrosis[J]. Int J Virol,2019,26(6):408-412.(in Chinese)曾钗明，卢世云，郭太林，等．肝脂肪变性与慢性乙型肝炎之间的关系及对肝纤维化的影响[J]．国际病毒学杂志，2019,26(6):408-412.

[14] WANG MM,WANG GS,SHEN F,et al. Hepatic steatosis is highly prevalent in hepatitis B patients and negatively associated with virological factors[J]. Dig Dig Sci,2014,59(10):2571-2579.

[15] LIANG J,LIU F,WANG F,et al. A noninvasive score model for prediction of NASH in patients with chronic hepatitis B and nonalcoholic fatty liver disease[J]. Biomed Res Int,2017,2017:8793278.

[16] XIAO G,ZHU S,XIAO X,et al. Comparison of laboratory tests,ultrasound,or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease:A meta-analysis[J]. Hepatology,2017,66(5):1486-1501.

施引文献

资源附件(0)

访问统计